The economic burden associated with prior authorizations in an allergist office.
Don A. Bukstein(Institute for Asthma and Allergy), Reid M. Olson, Allan T. Luskin(Dean Health Systems), Joshua Kooistra, Greeta A. Cherayil, Adam D. Gepner(University of Wisconsin Health)
PubMed
August 1, 2006
Cited by 10
Related Papers
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
|The Journal of Allergy and Clinical Immunology In Practice|2018|277
The economic impact of allergic rhinitis and current guidelines for treatment
|Annals of Allergy Asthma & Immunology|2011|268
Comparison of Carotid Plaque Score and Coronary Artery Calcium Score for Predicting Cardiovascular Disease Events: The Multi‐Ethnic Study of Atherosclerosis
|Journal of the American Heart Association|2017|169
Shared decision making for the allergist
|Annals of Allergy Asthma & Immunology|2018|119
The Challenges and Opportunities for Shared Decision Making Highlighted by COVID-19
|The Journal of Allergy and Clinical Immunology In Practice|2020|119